❤️ Three Different Things Keep Getting Called the Same Thing

Before evaluating any product claim, it’s worth being precise about terms that get used interchangeably in headlines but mean genuinely different things medically:

A heart attack (myocardial infarction) happens when blood flow to part of the heart muscle is blocked, usually by a clot, causing tissue damage. The heart is often still beating during a heart attack — the danger is the blocked artery, not that the heart has stopped.

Cardiac arrest is an electrical malfunction that causes the heart to stop beating effectively altogether. It’s immediately life-threatening in a different way — without CPR or defibrillation within minutes, survival drops sharply. A heart attack can trigger cardiac arrest, but they aren’t the same event.

Atrial fibrillation (AFib) is an irregular, often rapid heart rhythm originating in the heart’s upper chambers. It’s a real medical condition worth knowing about — it raises stroke risk — but on its own, a single AFib episode is not the acute emergency that a heart attack or cardiac arrest is.

Keeping these three separate matters for the rest of this article, because the wearable tech industry has meaningfully different levels of evidence for each one.

🔬 A Framework for Evaluating Cardiac Wearable Claims

• Tier 1: Established, FDA-cleared evidence. Large-scale clinical validation supporting a specific, regulator-reviewed claim. As detailed below, this tier exists for AFib detection — not for heart attack detection.
• Tier 2: Early clinical research. Real, published studies with real patient data, but small samples, narrow test conditions, or early-stage validation. This is where the most promising heart-attack- and cardiac-arrest-specific research currently sits.
• Tier 3: Engineering research and marketing claims. Proof-of-concept technology presented at conferences or in company marketing, without independent clinical validation in real-world patient use. A lot of the “AI detects heart attacks” headlines belong here.

✅ What’s Actually FDA-Cleared: AFib, Not Heart Attacks

Apple Watch’s ECG app and irregular rhythm notification feature received FDA De Novo classification in September 2018, as a Class II medical device available over-the-counter. This wasn’t a small approval — it was backed by the Apple Heart Study, which enrolled over 400,000 participants and remains one of the largest cardiovascular studies ever conducted, with a subset of that data submitted directly to the FDA to support clearance. A later update to the ECG feature added detection for AFib with high heart rate, with a reported specificity of 99.3% and sensitivity of 98.5% for that specific classification.

This isn’t a one-off result, either. A 2021 systematic review and meta-analysis published in the Journal of Medical Internet Research pooled data across multiple studies evaluating smartwatch arrhythmia detection broadly, finding an overall sensitivity of 100%, specificity of 95%, and accuracy of 97% for detecting cardiac arrhythmias — genuinely strong numbers for a consumer-accessible technology. The same review’s authors were careful to add an important caveat: while diagnostic accuracy is high, the field still needs stronger evidence accrual and clearer regulatory standards as these devices move toward broader clinical screening use. A separate 2022 review in Frontiers in Cardiovascular Medicine reached a similar conclusion — arrhythmia-detecting wearables are a genuinely evolving, evidence-backed field, but one with real diversity in device quality and a continued need for standardized validation before full integration into routine clinical practice.

In short: the real regulatory-grade wearable cardiac evidence that exists today is about catching an irregular rhythm you might not otherwise notice — not about detecting a heart attack as it happens.

🧪 The Research That Actually Targets Heart Attacks and Cardiac Arrest

A cardiac arrest detection wristband — real, but early. In May 2026, the American Heart Association published a study in the journal Circulation: Arrhythmia and Electrophysiology validating a smart wristband’s ability to detect cardiac arrest. The study analyzed data from 49 adults in the Netherlands who had a life-threatening heart rhythm briefly and deliberately induced during a medical procedure. Researchers described this as the first study to validate an algorithm-based wrist device using real patient data — an important early step, in their own words, not a finished, market-ready product. A study of 49 people, with the cardiac event induced under controlled medical conditions rather than occurring spontaneously in daily life, is real Tier 2 evidence — genuinely worth watching, not yet something to rely on.

A heart-attack-detecting chip — promising engineering, not yet a clinical study. Researchers at the University of Mississippi, led by electrical and computer engineering professor Kasem Khalil, developed a low-power chip that analyzes ECG signals in real time using a Fast Fourier Transform technique paired with an artificial neural network, classifying signals as normal or heart-attack-like. The team reported 92.4% accuracy, twice the detection speed of conventional methods, in a study published in the proceedings of the International Conference on Intelligent Systems, Blockchain and Communication Technologies. It’s worth being precise about what that publication venue means: a conference proceedings paper in engineering is a legitimate, real form of peer review, but it’s a different (and generally lighter) bar than publication in a clinical medical journal, and the available reporting on this work describes signal-classification performance rather than a prospective trial in real patients wearing the device day to day.

🚩 Where Marketing Gets Ahead of the Evidence

Some coverage of this category has moved well past what’s actually been validated — describing AI systems that can supposedly flag cardiac risk “weeks or even months before an event occurs” by combining wearable data, imaging analysis, and genetic profiling into a single predictive picture. That’s a much bigger claim than anything discussed above, and it’s presented in industry and marketing content without the kind of large-scale, peer-reviewed validation that exists for something like the Apple Heart Study. Treat this kind of long-range predictive framing as speculative until a specific product points to a specific, independently reviewed study behind it.

Separately, some cardiac wearable startups market a “detect cardiac arrest and automatically notify loved ones and emergency responders” concept directly to consumers. This is a compelling idea, and companies have raised real funding to pursue it — but a funding announcement is not clinical validation, and independent, published accuracy data for these specific consumer products in real-world use is generally not available. If a company doesn’t point you to a specific published study, that’s worth noticing.

📊 Quick Comparison

📋 Questions to Ask Before Trusting a Cardiac Wearable Claim

• Is this claim about AFib/arrhythmia, cardiac arrest, or an actual heart attack? These are different medical events with very different levels of evidence behind wearable detection.
• Is there FDA clearance for this specific claim, or just for a general “heart health tracking” feature? Apple’s AFib clearance is specific and real; many “heart health” claims in this category are not FDA-reviewed at all.
• Was this tested in real patients in daily life, or in a lab/engineering setting? The gap between a strong lab accuracy number and real-world reliability is significant, and worth asking about directly.
• What’s the false-positive rate, not just the accuracy rate? Given how rare true cardiac events are at any given moment, this number matters more than headline accuracy.
• Does the company point to a specific, independently published study — or just a funding announcement or marketing page?

🚑 What To Actually Do

None of this means wearables are useless for heart health — the AFib detection evidence is genuinely strong, and catching an undiagnosed irregular rhythm is a real benefit for some people. But for the specific question of heart attacks: no current wearable can reliably detect one as it’s happening, and none should be treated as a substitute for knowing the actual warning signs and acting on them. Classic heart attack symptoms include chest pain or pressure, pain spreading to the arm, jaw, or back, shortness of breath, cold sweat, nausea, or lightheadedness — and the correct response to any of these is to call emergency services immediately, not to wait and see what a wearable says. If you have diagnosed heart disease or risk factors, talk to your cardiologist about whether an FDA-cleared monitoring tool is appropriate for your specific situation, rather than choosing one based on marketing claims alone.

❓ Frequently Asked Questions

Can my Apple Watch detect a heart attack?

No. Apple Watch’s FDA-cleared features detect irregular heart rhythms consistent with atrial fibrillation (AFib), not heart attacks. AFib and heart attacks are different medical events, and the FDA clearance is specific to AFib detection.

Is there any wearable that can detect a heart attack?

Not yet, in an FDA-cleared, consumer-ready form. Real research exists — including an engineering proof-of-concept chip with 92.4% reported accuracy in signal classification — but it hasn’t yet been validated in a large-scale clinical trial or cleared by the FDA for this specific use.

What’s the difference between a heart attack and cardiac arrest?

A heart attack is caused by blocked blood flow to the heart muscle, and the heart is often still beating. Cardiac arrest is an electrical malfunction that causes the heart to stop beating effectively. A heart attack can lead to cardiac arrest, but they are not the same event, and wearable evidence for detecting each is at a different stage.

Should I rely on a smartwatch alert instead of calling 911 for heart attack symptoms?

No. No current wearable is validated to reliably detect a heart attack, and relying on one instead of recognizing symptoms and calling emergency services could delay critical care. Know the warning signs and act on them directly.

📚 Sources & References

• U.S. Food and Drug Administration, De Novo Classification Request for ECG App — regulatory decision summary (DEN180044)
• Apple Newsroom, “ECG app and irregular heart rhythm notification available today on Apple Watch”
• Healthcare Dive, “New Apple Watch adds FDA-cleared ECG application”
• MobiHealthNews, “Apple’s ECG feature can detect A-Fib with high HR thanks to new FDA clearance”
• American Heart Association Newsroom, “New smart technology in a wearable wristband may detect cardiac arrest”, Circulation: Arrhythmia and Electrophysiology, May 2026
• University of Mississippi (Ole Miss News), “UM Engineers Develop Wearable Heart Attack Detection Tech”
• ScienceDaily, “Engineers develop wearable heart attack detection tech”
• New Atlas, “University of Mississippi chip detects heart attacks in real time” (independent analysis of false-positive/base-rate considerations)
• Nazarian, S., Lam, K., Darzi, A., Ashrafian, H., “Diagnostic Accuracy of Smartwatches for the Detection of Cardiac Arrhythmia: Systematic Review and Meta-analysis,” Journal of Medical Internet Research, 2021
• Xintarakou, A., et al., “Remote Cardiac Rhythm Monitoring in the Era of Smart Wearables: Present Assets and Future Perspectives,” Frontiers in Cardiovascular Medicine, 2022

Verification notes: The Apple Heart Study and subsequent FDA De Novo clearances for AFib detection are independently, extensively documented and represent the strongest evidence tier in this article. The AHA cardiac-arrest wristband study is a real, newly published (May 2026) validation study, explicitly described by its own researchers as an early step using a small sample (49 adults) with medically induced arrhythmias, not spontaneous real-world events. The University of Mississippi chip’s 92.4% accuracy figure is real and traceable to a named research team and institution, but was published in engineering conference proceedings rather than a clinical journal, and available reporting does not describe a prospective human clinical trial — this distinction is treated as significant in the text above. Claims about AI predicting cardiac events “weeks or months” in advance, and consumer cardiac-arrest-alert wearables generally, are treated as Tier 3 marketing claims because independent, published, product-specific validation could not be located.

💡 The Bottom Line

The honest state of this category: real, strong, FDA-cleared evidence exists for wearables detecting AFib — a genuinely different problem than a heart attack. For actual heart attack and cardiac arrest detection, the research is real but early — a promising engineering proof-of-concept published at an academic conference, and a small, first-of-its-kind validation study using medically induced arrhythmias. Both are worth watching. Neither is a finished, clinically validated consumer product yet, whatever the marketing headlines might imply. If you’re evaluating wearable cardiac tech for yourself or a family member, our related look at cuffless blood pressure wearables and what’s actually FDA-cleared there covers a similar evidence-vs-marketing gap in an adjacent category, and is worth reading alongside this one.